The sweeter side of ACE2: Physiological evidence for a role in diabetes

Molecular and Cellular Endocrinology

Volumn 302, Issue 2, 2009, Pages 193-202

  Bindom, Sharell M ^a   Lazartigues, Eric ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Angiotensin converting enzyme 2; Beta cell dysfunction; Diabetes; Glucose homeostasis; Renin angiotensin system

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MLN 4760; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG;

CELL FUNCTION; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GENE DELETION; HUMAN; INSULIN RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PANCREAS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN I; ANIMALS; DIABETES MELLITUS; HUMANS; INSULIN RESISTANCE; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; RENIN-ANGIOTENSIN SYSTEM;

EID: 62949127898     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.09.020     Document Type: Review

References (157)

1. Abuissa H., Jones P.G., Marso S.P., and O'Keefe J.J.H. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. 46 (2005) 821-826
2. Almeida A.P., Frábregas B.C., Madureira M.M., Santos R.J.S., Campagnole-Santos M.J., and Santos R.A.S. Angiotensin-(1-7) potentiates the coronary vasodilatatory effect of bradykinin in the isolated rat heart. Braz. J. Med. Biol. Res. 33 (2000) 709-713
3. Anonymous. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 317 (1998) 713-720
4. Anonymous. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355 (2000) 253-259
5. Anonymous. Type 2 diabetes in children and adolescents. American Diabetes Association. Diabetes Care 23 (2000) 1442-1443
6. Atef N., Ktorza A., Picon L., and Penicaud L. Increased islet blood flow in obese rats: role of the autonomic nervous system. Am. J. Physiol. Endocrinol. Metab. 262 (1992) E736-740
7. Atef N., Portha B., and Pénicaud L. Changes in islet blood flow in rats with NIDDM. Diabetologia 37 (1994) 677-680
8. Bader M., Peters J., Baltatu O., Müller D.N., and Luft F.C. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J. Mol. Med. 79 (2001) 76-102
9. Baltatu O., Silva Jr. J.A., Ganten D., and Bader M. The brain renin-angiotensin system modulates angiotensin II-induced hypertension and cardiac hypertrophy. Hypertension 35 1 Pt 2 (2000) 409-412
10. Baron A.D., Laakso M., Brechtel G., and Edelman S.V. Mechanism of insulin resistance in insulin-dependent diabetes mellitus: a major role for reduced skeletal muscle blood flow. J. Clin. Endocrinol. Metab. 73 (1991) 637-643
11. Bataller R., Sancho-bru P., Ginès P., Lora J.M., Al-garawi A., Solé M., Colmenero J., Nicolás J.M., Jiménez W., Weich N., Gutiérrez-ramos J.-c., Arroyo V., and Rodés J. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 125 (2003) 117-125
12. Beard K.M., Lu H., Ho K., and Fantus I.G. Bradykinin augments insulin-stimulated glucose transport in rat adipocytes via endothelial nitric oxide synthase-mediated inhibition of Jun NH2-terminal kinase. Diabetes 55 (2006) 2678-2687
13. Bindokas V.P., Kuznetsov A., Sreenan S., Polonsky K.S., Roe M.W., and Philipson L.H. Visualizing superoxide production in normal and diabetic rat islets of Langerhans. J. Biol. Chem. 278 (2003) 9796-9801
14. Branton M.H., and Kopp J.B. TGF-beta and fibrosis. Microbes Infect. 1 (1999) 1349-1365
15. Brosnihan K.B., Li P., and Ferrario C.M. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27 (1996) 523-528
16. Carlsson P.-O. The renin-angiotensin system in the endocrine pancreas. JOP 2 (2001) 26-32
17. Carlsson P.O., Andersson A., and Jansson L. Pancreatic islet blood flow in normal and obese-hyperglycemic (ob/ob) mice. Am. J. Physiol. Endocrinol. Metab. 271 (1996) E990-E995
18. Carlsson P.O., Berne C., and Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41 (1998) 127-133
19. Carlsson P.O., Jansson L., Ostenson C.G., and Kallskog O. Islet capillary blood pressure increase mediated by hyperglycemia in NIDDM GK rats. Diabetes 46 (1997) 947-952
20. Chappell M., Millsted A., Diz D., Brosnihan K., and Ferrario C.M. Evidence for an intrinsic angiotensin system in the canine pancreas. J. Hypertens. 9 (1991) 751-759
21. Clark A., and Nilsson M.R. Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes?. Diabetologia 47 (2004) 157-169
22. Clark J., Palmer C., and Shaw W. The diabetic Zucker fatty rat. Proc. Soc. Exp. Biol. Med. 17 (1983) 68-75
23. Curry D., Bennett L., and Grodsky G.M. Dynamics of insulin secretion by the perfused rat pancreas. Endocrinology 83 (1968) 572-584
24. da Costa Goncalves A.C., Leite R., Fraga-Silva R.A., Pinheiro S.V., Reis A.B., Reis F.M., Touyz R.M., Webb R.C., Alenina N., Bader M., and Santos R.A.S. Evidence that the vasodilator angiotensin-(1-7)-Mas axis plays an important role in erectile function. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H2588-2596
25. Dabelea D., Hanson R.L., Bennett P.H., Roumain J., Knowler W.C., and Pettitt D.J. Increasing prevalence of Type II diabetes in American Indian children. Diabetologia 41 (1998) 904-910
26. Dabelea D., Pettitt D.J., Jones K.L., and Arslanian S.A. Type 2 diabetes mellitus in minority children and adolescents. An emerging problem. Endocrinol. Metab. Clin. North Am. 28 (1999) 709-729
27. Dalla Vestra M., Masiero A., Roiter A.M., Saller A., Crepaldi G., and Fioretto P. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 52 (2003) 1031-1035
28. Danilczyk U., Sarao R., Remy C., Benabbas C., Stange G., Richter A., Arya S., Pospisilik J.A., Singer D., Camargo S.M.R., Makrides V., Ramadan T., Verrey F., Wagner C.A., and Penninger J.M. Essential role for collectrin in renal amino acid transport. Nature 444 (2006) 1088-1091
29. Danser A.H.J., and Schalekamp M.A.D.H. Is there an internal cardiac renin-angiotensin system?. Heart 76 (1996) 28-32
30. de Cavanagh E.M.V., Inserra F., Toblli J., Stella I., Fraga C.G., and Ferder L. Enalapril attenuates oxidative stress in diabetic rats. Hypertension 38 (2001) 1130-1136
31. Diez-Freire C., Vazquez J., Correa de Adjounian M.F., Ferrari M.F.R., Yuan L., Silver X., Torres R., and Raizada M.K. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol. Genomics 27 (2006) 12-19
32. Donath M.Y., Størling J., Maedler K., and Mandrup-Poulsen T. Inflammatory mediators and islet ß-cell failure: a link between type 1 and type 2 diabetes. J. Mol. Med. 81 (2003) 455-470
33. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R., Breitbart R.E., and Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87 (2000) E1-E9
34. Drake A.J., Smith A., Betts P.R., Crowne E.C., and Shield J.P.H. Type 2 diabetes in obese white children. Arch. Dis. Child. 86 (2002) 207-208
35. Dzau V.J., and Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift?. Circulation 89 (1994) 493-498
36. Ehtisham S., Barrett T.G., and Shaw N.J. Type 2 diabetes mellitus in UK children-an emerging problem. Diabet. Med. 17 (2000) 867-871
37. Evans J.L., Goldfine I.D., Maddux B.A., and Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev. 23 (2002) 599-622
38. Feng Y., Yue X., Xia H., Bindom S.M., Hickman P., Filipeanu C., Wu G., and Lazartigues E. ACE2 over-expression in the subfornical organ prevents the angiotensin-II-mediated pressor and drinking responses and is associated with AT1 receptor down-regulation. Circ. Res. 102 (2008) 628-629
39. Fernandes L., Fortes Z.B., Nigro D., Tostes R.C.A., Santos R.A.S., and Catelli de Carvalho M.H. Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension 37 (2001) 703-709
40. Ferreira A.J., and Raizada M.K. Genomic and proteomic approaches for targeting angiotensin converting enzyme2 for cardiovascular diseases. Curr. Opin. Cardiol. 23 (2008) 364-369
41. Fliser D., Schaefer F., Schmid D., Veldhuis J.D., and Ritz E. Angiotensin II affects basal, pulsatile, and glucose-stimulated insulin secretion in humans. Hypertension 30 (1997) 1156-1161
42. Fossum E., Hoieggen A., Moan A., Rostrup M., Nordby G., and Kjeldsen S.E. Relationship between insulin sensitivity and maximal forearm blood flow in young men. Hypertension 32 (1998) 838-843
43. Frisbee J.C. Vascular adrenergic tone and structural narrowing constrain reactive hyperemia in skeletal muscle of obese Zucker rats. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H2066-H2074
44. Fueger P.T., Bracy D.P., Malabanan C.M., Pencek R.R., and Wasserman D.H. Distributed control of glucose uptake by working muscles of conscious mice: roles of transport and phosphorylation. Am. J. Physiol. Endocrinol. Metab. 286 (2004) E77-E84
45. Gallagher P.E., Chappell M.C., Bernish B.W., and Tallant E.A. ACE2 expression in brain: angiotensin II down-regulates ACE2 in astrocytes. Abstract Presented at the 57th Annual Fall Conference and Scientific sessions of the Council for High Blood Pressure Research (2003)
46. Galvez-Prieto B., Bolbrinker J., Stucchi P., de las Heras A.I., Merino B., Arribas S., Ruiz-Gayo M., Huber M., Wehland M., Kreutz R., and Fernandez-Alfonso M.S. Comparative expression analysis of the renin-angiotensin system components between white and brown perivascular adipose tissue. J. Endocrinol. 197 (2008) 55-64
47. Gembardt F., Sterner-Kock A., Imboden H., Spalteholz M., Reibitz F., Schultheiss H.-P., Siems W.-E., and Walther T. Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides 26 (2005) 1270-1277
48. Gerich J.E. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes?. Diabetes 51 (2002) S117-S121
49. Gironacci M.M., Valera M.S., Yujnovsky I., and Pena C. Angiotensin-(1-7) inhibitory mechanism of norepinephrine release in hypertensive rats. Hypertension 44 (2004) 783-787
50. Grankvist K., Marklund S., and Taljedal I. CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. Biochem. J. 199 (1981) 393-398
51. Gress T.W., Nieto F.J., Shahar E., Wofford M.R., and Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N. Engl. J. Med. 342 (2000) 905-912
52. Griendling K.K., Minieri C.A., Ollerenshaw J.D., and Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74 (1994) 1141-1148
53. Grobe J.L., Der sarkissian S., Stewart J.M., Meszaros J.G., Raizada M.K., and Katovich M.J. ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin. Sci. (Lond.) 113 (2007) 357-364
54. Grundy S.M., Benjamin I.J., Burke G.L., Chait A., Eckel R.H., Howard B.V., Mitch W., Smith Jr. S.C., and Sowers J.R. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100 (1999) 1134-1146
55. Gurley S.B., Allred A., Le T.H., Griffiths R., Mao L., Philip N., Haystead T.A., Donoghue M., Breitbart R.E., Acton S.L., Rockman H.A., and Coffman T.M. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J. Clin. Invest. 116 (2006) 2218-2225
56. Guy J.L., Jackson R.M., Acharya K.R., Sturrock E.D., Hooper N.M., and Turner A.J. Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry 42 (2003) 13185-13192
57. Harmon J.S., Stein R., and Robertson R.P. Oxidative stress-mediated, post-translational loss of MafA protein as a contributing mechanism to loss of insulin gene expression in glucotoxic beta cells. J. Biol. Chem. 280 (2005) 11107-11113
58. Harrison D.G., Gongora M.C., Guzik T.J., and Widder J. Oxidative stress and hypertension. JASH 1 (2007) 30-44
59. Hayden M., Karuparthi P., Habibi J., Waseker C., Lastra G., Marnrique C., Stas S., and Sowers J. Ultrastructural islet study of early fibrosis in the Ren2 model of hypertension. Emerging role of the islet pancreatic pericyte-stellate cell. JOP 8 (2007) 725-738
60. Hayden M., and Tyagi S. Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus. JOP 3 (2002) 86-108
61. Heitsch H., Brovkovych S., Malinski T., and Wiemer G. Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells. Hypertension 37 (2001) 72-76
62. Henriksen E.J., Jacob S., Kinnick T.R., Youngblood E.B., Schmit M.B., and Dietze G.J. ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide. Am. J. Physiol. Regul. Integr. Comp. Physiol. 277 (1999) R332-R336
63. Herath C., Warner F.J., Lubel J., Dean R.J., Jia Z., Lew R.A., Smith A.I., Burrell L.M., and Angus P.W. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental billiary fibrosis. J. Hepatol. 47 (2007) 387-395
64. Huang L., Sexton D.J., Skogerson K., Devlin M., Smith R., Sanyal I., Parry T., Kent R., Enright J., Wu Q.L., Conley G., DeOliveira D., Morganelli L., Ducar M., Wescott C.R., and Ladner R.C. Novel peptide inhibitors of angiotensin-converting enzyme 2. J. Biol. Chem. 278 (2003) 15532-15540
65. Huentelman M.J., Grobe J.L., Vazquez J., Stewart J.M., Mecca A.P., Katovich M.J., Ferrario C.M., and Raizada M.K. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp. Physiol. 90 (2005) 783-790
66. Imai Y., Kuba K., and Penninger J.M. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp. Physiol. 93 (2008) 543-548
67. Imai Y., Kuba K., Rao S., Huan Y., Guo F., Guan B., Yang P., Sarao R., Wada T., Leong-Poi H., Crackower M.A., Fukamizu A., Hui C.-C., Hein L., Uhlig S., Slutsky A.S., Jiang C., and Penninger J.M. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436 (2005) 112-116
68. Jansson L., and Sandler S. Pancreatic and islet blood flow in the regenerating pancreas after a partial pancreatectomy in adult rats. Surgery 106 (1981) 861-866
69. Johnson J.D., Ahmed N.T., Luciani D.S., Han Z., Tran H., Fujita J., Misler S., Edlund H., and Polonsky K.S. Increased islet apoptosis in Pdx1 ± mice. J. Clin. Invest. 111 (2003) 1147-1160
70. Kaneto H., Xu G., Song K.-H., Suzuma K., Bonner-Weir S., Sharma A., and Weir G.C. Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress. J. Biol. Chem. 276 (2001) 31099-31104
71. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
72. Kishi K., Muromoto N., Nakaya Y., Miyata I., Hagi A., Hayashi H., and Ebina Y. Bradykinin directly triggers GLUT4 translocation via an insulin-independent pathway. Diabetes 47 (1998) 550-558
73. Konoshita T., Wakahara S., Mizuno S., Motomura M., Aoyama C., Makino Y., Kawai Y., Kato N., Koni I., Miyamori I., and Mabuchi H. Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy. Diabetes Care 4 (2006) 848-852
74. Laakso M., Edelman S.V., Brechtel G., and Baron A.D. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J. Clin. Invest. 85 (1990) 1844-1852
75. Laine H., Yki-Jarvinen H., Kirvela O., Tolvanen T., Raitakari M., Solin O., Haaparanta M., Knuuti J., and Nuutila P. Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity. J. Clin. Invest. 101 (1998) 1156-1162
76. Lambert D.W., Yarski M., Warner F.J., Thornhill P., Parkin E.T., Smith A.I., Hooper N.M., and Turner A.J. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem. 280 (2005) 30113-30119
77. Langheinrich M., Ae Lee M., Böhm M., Pinto Y.M., Ganten D., and Paul M. The hypertensive Ren-2 transgenic rat TGR (mREN2)27 in hypertension research. Characteristics and functional aspects. Am. J. Hypertens. 9 (1996) 506-512
78. Lau T., Carlsson P.O., and Leung P.S. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 47 (2004) 240-248
79. Lavoie J.L., and Sigmund C.D. Minireview: overview of the renin-angiotensin system-an endocrine and paracrine system. Endocrinology 144 (2003) 2179-2183
80. Leung P., Chan H., and Wong P. Immunohistochemical localization of angiotensin II in the mouse pancreas. Histochem. J. 30 (1998) 21-25
81. Leung P.S. The physiology of a local renin-angiotensin system in the pancreas. J. Physiol. 580 (2007) 31-37
82. Leung P.S., Chan W.P., Wong T.P., and Sernia C. Expression and localization of the renin-angiotensin system in the rat pancreas. J. Endocrinol. 160 (1999) 13-19
83. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H., and Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (2003) 450-454
84. Lima C.V., Paula R.D., Resende F.L., Khosla M.C., and Santos R.A.S. Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats. Hypertension 30 (1997) 542-548
85. Lupi R., Guerra S.D., Bugliani M., Boggi U., Mosca F., Torri S., Prato S.D., and Marchetti P. The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur. J. Endocrinol. 154 (2006) 355-361
86. Maechler P., Jornot L., and Wollheim C.B. Hydrogen peroxide alters mitochondrial activation and insulin secretion in pancreatic beta cells. J. Biol. Chem. 274 (1999) 27905-27913
87. Mason J.M., Dickenson H.O., Nicholson D.J., Campbel F., Ford G., and Williams B. The diabetogenic potential of thiazide-type and beta blocker combinations in patients with hypertension. J. Hypertens. 23 (2005) 1777-1781
88. Matsuoka T.-A., Kajimoto Y., Watada H., Kaneto H., Kishimoto M., Umayahara Y., Fujitani Y., Kamada T., Kawamori R., and Yamasaki Y. Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J. Clin. Invest. 99 (1997) 144-150
89. Meyer T.W., Bennett P.H., and Nelson R.G. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 42 (1999) 1341-1344
90. Mezzano S.A., Ruiz-Ortega M., and Egido J. Angiotensin II and renal fibrosis. Hypertension 38 (2001) 635-638
91. Mizuiri S., Hemmi H., Arita M., Ohashi Y., Tanaka Y., Miyagi M., Sakai K., Ishikawa Y., Shibuya K., Hase H., and Aikawa A. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am. J. Kidney Dis. 51 (2008) 613-623
92. Moldovan S., Livingston E., Zhang R.S., Kleinman R., Girth P., and Brunicardi F.C. Glucose-induced islet hyperemia is mediated by nitric oxide. Am. J. Surg. 171 (1996) 16-20
93. Nakayama M., Inoguchi T., Sonta T., Maeda Y., Sasaki S., Sawada F., Tsubouchi H., Sonoda N., Kobayashi K., Sumimoto H., and Nawata H. Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochem. Biophys. Res. Commun. 332 (2005) 927-933
94. Neufeld N.D., Raffel L.J., Landon C., Chen Y.D., and Vadheim C.M. Early presentation of type 2 diabetes in Mexican-American youth. Diabetes Care 21 (1998) 80-86
95. Niklason A., Hedner T., Kiskanen L., and Lanke J. Development of diabetes is retarded by ACE inhibition in hypertensive patients: a sub-analysis of the Captopril Prevention Project. J. Hypertens. 38 (2004) E28-E32
96. Oliveira H.R., Verlengia R., Carvalho C.R.O., Britto L.R.G., Curi R., and Carpinelli A.R. Pancreatic beta-cells express phagocyte-like NAD(P)H oxidase. Diabetes 52 (2003) 1457-1463
97. Oliveira M.A., Bruno Fortes Z.B., Santos R.A., Kosla M.C., and De Carvalho M.H. Synergistic effect of angiotensin-(1-7) on bradykinin arteriolar dilation in vivo. Peptides 20 (1999) 1195-1201
98. Oliveira M.A., Carvalho M.H.C., Nigro D., Passaglia R.d.C.A.T., and Fortes Z.B. Angiotensin-(1-7) and bradykinin interaction in diabetes mellitus: in vivo study. Peptides 23 (2002) 1449-1455
99. Pagtalunan M., Miller P., Jumping-Eagle S., Nelson R., Myers R., Rennke H., Coplon N., Sun L., and Meyer T. Podocyte loss and progressive glomerular injury in type II diabetes. J. Clin. Invest. 99 (1997) 342-348
100. Paizis G., Cooper M.E., Schembri J.M., Tikellis C., Burrell L.M., and Angus P.W. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 123 (2002) 1667-1676
101. Paizis G., Tikellis C., Cooper M.E., Schembri J.M., Lew R.A., Smith A.I., Shaw T., Warner F.J., Zuilli A., Burrell L.M., and Angus P.W. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut 54 (2005) 1790-1796
102. Paul M., Poyan Mehr A., and Kreutz R. Physiology of local renin-angiotensin systems. Physiol. Rev. 86 (2006) 747-803
103. Paula R.D., Lima C.V., Khosla M.C., and Santos R.A.S. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension 26 (1995) 1154-1159
104. Peltoniemi P., Yki-Jarvinen H., Oikonen V., Oksanen A., Takala T.O., Ronnemaa T., Erkinjuntti M., Knuuti M.J., and Nuutila P. Resistance to exercise-induced increase in glucose uptake during hyperinsulinemia in insulin-resistant skeletal muscle of patients with type 1 diabetes. Diabetes 50 (2001) 1371-1377
105. Pinhas-Hamiel O., and Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J. Pediatr. 146 (2005) 693-700
106. Portsi I., Bara A., Busse R., and Hecker M. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br. J. Pharmacol. 111 (1994) 652-654
107. Rastelli V.M.F., Oliveira M.A., dos Santos R., de Cássia Tostes Passaglia R., Nigro D., de Carvalho M.H.C., and Fortes Z.B. Lack of potentiation of bradykinin by angiotensin-(1-7) in a type 2 diabetes model: role of insulin. Peptides 28 (2007) 1040-1049
108. Reid C.M., Johnston C.I., Ryan P., Willson K., and Wing L.M. Diabetes and cardiovascular outcomes in elderly subjects treated with ace-inhibitors or diuretics: findings from the 2ND Australian national blood pressure study. Am. J. Hypertens. 16 (2003) A11
109. Robertson R.P. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J. Biol. Chem. 279 (2004) 42351-42354
110. Samols E., and Stagner J. Intra-islet regulation. Am. J. Med. 85 (1988) 31-35
111. Sampaio W.O., Souza dos Santos R.A., Faria-Silva R., da Mata Machado L.T., Schiffrin E.L., and Touyz R.M. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49 (2007) 185-192
112. Santos R.A., Campagnole-Santos M.J., Baracho N.C., Fontes M.A., Silva L.C., Neves L.A., Oliveira D.R., Caligiorne S.M., Rodrigues A.R., Gropen Júnior C., et al. Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res. Bull. 35 (1994) 293-298
113. Santos R.A.S., e Silva A.C.S., Maric C., Silva D.M.R., Machado R.P., de Buhr I., Heringer-Walther S., Pinheiro S.V.B., Lopes M.T., Bader M., Mendes E.P., Lemos V.S., Campagnole-Santos M.J., Schultheiss H.-P., Speth R., and Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 8258-8263
114. Santos S.H.S., Fernandes L.R., Mario E.G., Ferreira A.V.M., Porto L.C.J., Alvarez-Leite J.I., Botion L.M., Bader M., Alenina N., and Santos R.A.S. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 57 (2007) 340-347
115. Schmid H., Henger A., Cohen C.D., Frach K., Grone H.-J., Schlondorff D., and Kretzler M. Gene expression profiles of podocyte-associated molecules as diagnostic markers in acquired proteinuric diseases. J. Am. Soc. Nephrol. 14 (2003) 2958-2966
116. Shao J., Iwashita N., Ikeda F., Ogihara T., Uchida T., Shimizu T., Uchino H., Hirose T., Kawamori R., and Watada H. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on [beta]-cell function and morphology in db/db mice. Biochem. Biophys. Res. Commun. 344 (2006) 1224-1233
117. Shao Y., He M., Zhou L., Yao T., Huang Y., and Lu L.M. Chronic angiotensin (1-7) injection accelerates STZ-induced diabetic renal injury. Acta Pharmacol. Sin. 29 (2008) 829-837
118. Soler M.J., Wysocki J., Ye M., Lloveras J., Kanwar Y., and Batlle D. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int. 72 (2007) 614-623
119. Steinberg H., Chaker H., Leaming R., Johnson A., Brechtel G., and Baron A.D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 97 (1996) 2601-2610
120. Styrud J., Eriksson U.J., and Jansson L. A continuous 48-hour glucose infusion in rats causes both an acute and a persistent redistribution of the blood flow within the pancreas. Endocrinology 130 (1992) 2692-2696
121. Susztak K., Raff A.C., Schiffer M., and Bottinger E.P. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55 (2006) 225-233
122. Suzuki Y., Ruiz-Ortega M., Lorenzo O., Ruperez M., Esteban V., and Egido J. Inflammation and angiotensin II. Int. J. Biochem. Cell. Biol. 35 (2003) 881-900
123. Tahmasebi M., Puddefoot J.R., Inwang E.R., and Vinson G.P. The tissue renin-angiotensin system in human pancreas. J. Endocrinol. 161 (1999) 317-322
124. Tallant E.A., Ferrario C.M., and Gallagher P.E. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H1560-H1566
125. Tang C., Han P., Oprescu A.I., Lee S.C., Gyulkhandanyan A.V., Chan G.N.Y., Wheeler M.B., and Giacca A. Evidence for a role of superoxide generation in glucose-induced beta cell dysfunction in vivo. Diabetes 56 (2007) 2722-2731
126. Tikellis C., Bialkowski K., Pete J., Sheehy K., Su Q., Johnston C., Cooper M.E., and Thomas M.C. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 57 (2008) 1018-1025
127. Tikellis C., Cooper M.E., and Thomas M.C. Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes. Int. J. Biochem. Cell. Biol. 38 (2006) 737-751
128. Tikellis C., Johnston C., Forbes J., Burns W., Thomas M., Lew R., Yarski M., Smith A., and Cooper M. Identification of angiotensin converting enzyme 2 in the rodent retina. Curr. Eye Res. 29 (2004) 419-427
129. Tikellis C., Wookey P.J., Candido R., Andrikopoulos S., Thomas M.C., and Cooper M.E. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 53 (2004) 989-997
130. Tikellis C., Johnston C.I., Forbes J.M., Burns W.C., Burrell L.M., Risvanis J., and Cooper M.E. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41 (2003) 392-397
131. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., and Turner A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 275 (2000) 33238-33243
132. Toblli J.E., Munoz M.C., Cao G., Mella J., Pereyra L., and Mastai R. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese zucker rats. Obesity 16 (2007) 770-776
133. Torlone E., Rambotti A.M., Perriello G., Botta G., Santeusanio F., Brunetti P., and Bolli G.B. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with Type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. Diabetologia 34 (1991) 119-125
134. Tsubouchi H., Inoguchi T., Inuo M., Kakimoto M., Sonta T., Sonoda N., Sasaki S., Kobayashi K., Sumimoto H., and Nawata H. Sulfonylurea as well as elevated glucose levels stimulate reactive oxygen species production in the pancreatic [beta]-cell line, MIN6-a role of NAD(P)H oxidase in [beta]-cells. Biochem. Biophys. Res. Commun. 326 (2004) 60-65
135. Uchizono Y., Takeya R., Iwase M., Sasaki N., Oku M., Imoto H., Iida M., and Sumimoto H. Expression of isoforms of NADPH oxidase components in rat pancreatic islets. Life Sci. 80 (2006) 133-139
136. Utriainen T., Takala T., Luotolahti M., Rönnemaa T., Laine H., Ruotsalainen U., Haaparanta M., Nuutila P., and Yki-Järvinen H. Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM. Diabetologia 41 (1998) 555-559
137. Valdés G., Neves L.A.A., Anton L., Corthorn J., Chacón C., Germain A.M., Merrill D.C., Ferrario C.M., Sarao R., Penninger J., and Brosnihan K.B. Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies. Placenta 27 (2006) 200-207
138. Vermes E., Ducharme A., Bourassa M.G., Lessard M., White M., and Tardif J.-C. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 107 (2003) 1291-1296
139. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M., Nichols A., and Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277 (2002) 14838-14843
140. Weber K., Brilla C., Campbell S., Guarda E., Zhou G., and Sriram K. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res. Cardiol. 88 (1993) 107-124
141. Wiemer G., Dobrucki L.W., Louka F.R., Malinski T., and Heitsch H. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 40 (2002) 852-875
142. Williams S.B., Cusco J.A., Roddy M.A., Johnstone M.T., and Creager M.A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 27 (1996) 567-574
143. Wong D.W., Oudit G.Y., Reich H., Kassiri Z., Zhou J., Liu Q.C., Backx P.H., Penninger J.M., Herzenberg A.M., and Scholey J.W. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am. J. Pathol. 171 (2007) 438-451
144. Wu L., Nicholson W., Knobel S.M., Steffner R.J., May J.M., Piston D.W., and Powers A.C. Oxidative stress is a mediator of glucose toxicity in insulin-secreting pancreatic islet cell lines. J. Biol. Chem. 279 (2004) 12126-12134
145. Wysocki J., Ye M., Soler M.J., Gurley S.B., Xiao H.D., Bernstein K.E., Coffman T.M., Chen S., and Batlle D. ACE and ACE2 activity in diabetic mice. Diabetes 55 (2006) 2132-2139
146. Xiang L., Dearman J., Abram S.R., Carter C., and Hester R.L. Insulin resistance and impaired functional vasodilation in obese Zucker rats. Am. J. Physiol. Heart Circ. Physiol. 294 (2008) H1658-H1666
147. Yamamoto K., Ohishi M., Katsuya T., Ito N., Ikushima M., Kaibe M., Tatara Y., Shiota A., Sugano S., Takeda S., Rakugi H., and Ogihara T. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47 (2006) 718-726
148. Yamamoto T., Nakamura T., Noble N.A., Ruoslahti E., and Border W.A. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 1814-1818
149. Yamazato M., Yamazato Y., Sun C., Diez-Freire C., and Raizada M.K. Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension 49 (2007) 926-931
150. Ye M., Wysocki J., Naaz P., Salabat M.R., LaPointe M.S., and Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination?. Hypertension 43 (2004) 1120-1125
151. Ye M., Wysocki J., William J., Soler M.J., Cokic I., and Batlle D. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J. Am. Soc. Nephrol. 17 (2006) 3067-3075
152. Yoshioka M., Kayo T., Ikeda T., and Koizumi A. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 46 (1997) 887-894
153. Yu D., Petermann A., Kunter U., Rong S., Shankland S.J., and Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J. Am. Soc. Nephrol. 16 (2005) 1733-1741
154. Yusuf S., Gerstein H., Hoogwerf B., Pogue J., Bosch J., Wolffenbuttel B.H.R., Zinman B., and for the H.S.I. Ramipril and the development of diabetes. JAMA 286 (2001) 1882-1885
155. Zhang H., Wada J., Hida K., Tsuchiyama Y., Hiragushi K., Shikata K., Wang H., Lin S., Kanwar Y.S., and Makino H. Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. J. Biol. Chem. 276 (2001) 17132-17139
156. Zhang Y., Wada J., Yasuhara A., Iseda I., Eguchi J., Fukui K., Yang Q., Yamagata K., Hiesberger T., Igarashi P., Zhang H., Wang H., Akagi S., Kanwar Y., and Makino H. The role for HNF-1β-targeted collectrin in maintenance of primary cilia and cell polarity in collecting duct cells. PLos ONE 2 (2007) e414
157. Zhong J.C., Yu X.Y., Lin Q.X., Li X.H., Huang X.Z., Xiao D.Z., and Lin S.G. Enhanced angiotensin converting enzyme 2 regulates the insulin//Akt signalling pathway by blockade of macrophage migration inhibitory factor expression. Br. J. Pharmacol. (2007)